Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Solas BioVentures is an early-stage venture capital firm founded in 2015 and based in Chattanooga, Tennessee. The firm specializes in the life sciences sector, focusing on biopharmaceuticals, medical devices, and digital health. With a fund size of $100 million, Solas BioVentures operates globally, targeting early-stage opportunities that demonstrate a clear path to commercialization. The firm has established itself as a significant player in the life sciences investment landscape, leveraging its extensive expertise in medical, biotech, operational, and financial domains.
The firm’s founder-centric approach is designed to support innovative companies in the life sciences sector, ensuring that entrepreneurs receive the guidance and resources necessary for successful commercialization. Solas BioVentures has built a diverse portfolio of companies, reflecting its commitment to fostering breakthrough innovations that can significantly impact healthcare outcomes.
Solas BioVentures invests exclusively in the life sciences sector, with a particular emphasis on biopharmaceuticals, medical devices, and digital health. The firm targets early-stage opportunities, including pre-seed, seed, and seed+ (extension) rounds, with typical check sizes ranging from $250,000 to $5 million. This investment strategy is designed to enable breakthrough innovations that can transform healthcare delivery and improve patient outcomes.
The firm seeks to partner with founders who demonstrate a strong vision and a clear path to commercialization. Solas BioVentures values deep industry knowledge and operational expertise, which are critical for navigating the complexities of the life sciences market. Their investment thesis centers on fostering innovation through a founder-centric approach, ensuring that portfolio companies receive tailored support throughout their development journey.
Solas BioVentures has built a notable portfolio of companies in the life sciences sector. Key investments include:
David Adair, MD, MBA - Co-Founder & Managing Director. He has extensive experience in the medical and biotech fields, focusing on operational and financial strategies.
Mark Hackett, JD - Co-Founder & Partner. He brings legal expertise and a strong background in healthcare administration.
David Belitz - Partner. He has a background in venture capital and operational management within the life sciences sector.
Michael Hoey, PhD, MBA - Partner. His expertise lies in medical technology and operational strategies.
Michael Ackermann, PhD - Partner and CCO of Arrivo BioVentures, contributing significant industry knowledge.
Lana Caron - Partner. She has a strong background in healthcare investments and operational management.
Travis Manasco, MD - Partner. He brings clinical expertise and insights into medical innovations.
Joshua Eckelberry, MBA - Partner. He has experience in financial management and venture capital.
Julia Ray, BS - Controller. She manages financial operations and reporting.
Laurent Pacheco, MD, PhD, MBA - Investor Relations. He focuses on building relationships with investors and stakeholders.
To pitch Solas BioVentures, startups should submit their proposals through the firm’s website at solasbio.com. The pitch deck should include a comprehensive overview of the business model, market analysis, and financial projections. Solas BioVentures prefers warm introductions but will consider direct submissions. Response times may vary, but founders can expect feedback within a few weeks.
In November 2021, Solas BioVentures announced the hiring of Jarrett Millsaps as Managing Director, bringing over 20 years of executive experience in healthcare administration to the team.
In 2022, Solas BioVentures led a $17 million financing round for AEGEA Medical, further solidifying its commitment to supporting innovative healthcare solutions.
Additionally, the firm co-led a $16 million Series A round for Vektor Medical, showcasing its active role in funding promising life sciences companies.
What are Solas BioVentures' investment criteria?
Solas BioVentures invests exclusively in the life sciences sector, focusing on early-stage opportunities in biopharmaceuticals, medical devices, and digital health. The firm looks for companies with a clear path to commercialization and a strong founding team.
How can startups apply or pitch to Solas BioVentures?
Startups can pitch to Solas BioVentures through their website at solasbio.com. It is recommended to include a detailed business plan and financial projections in the pitch deck.
What makes Solas BioVentures different from other VC firms?
The firm emphasizes a founder-centric approach, providing tailored support and leveraging deep expertise in medical, biotech, operational, and financial domains to guide portfolio companies towards successful commercialization.
What is the geographic scope of Solas BioVentures?
Solas BioVentures operates on a global scale, targeting early-stage life sciences companies worldwide.
What is the typical fund size and check size for investments?
The firm has a fund size of $100 million, with typical check sizes ranging from $250,000 to $5 million.
What is the post-investment involvement of Solas BioVentures?
Solas BioVentures actively engages with its portfolio companies, providing operational support, strategic guidance, and access to their extensive network to help drive growth and innovation.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.